ATP-binding cassette transporters at the blood-brain barrier in ischaemic stroke

Current Pharmaceutical Design

Volumn 17, Issue 26, 2011, Pages 2787-2792

  Patak, Pauline ^a   Hermann, Dirk M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

ABC transporters; Blood brain barrier; Ischaemic stroke; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; ALTEPLASE; APOLIPOPROTEIN E; DISUFENTON SODIUM; DOMPERIDONE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPID; MULTIDRUG RESISTANCE PROTEIN 1; NEUROPROTECTIVE AGENT; NORPHENAZONE; REACTIVE OXYGEN METABOLITE; RIFAMPICIN; TACROLIMUS; TARIQUIDAR; TIRILAZAD; VERAPAMIL;

BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN CAPILLARY; BRAIN ISCHEMIA; BRAIN TISSUE; CAPILLARY ENDOTHELIUM; DRUG ACCUMULATION; DRUG EFFICACY; HUMAN; HYPOXIA; INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

EID: 80053549905     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797440195     Document Type: Review

References (62)

1. Truelsen T, Bonita R. The worldwide burden of stroke: current status and future projections. Handb Clin Neurol 2009; 92: 327-36.
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-7.
3. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53: 569-96.
4. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98.
5. Hermann DM, Kilic E, Spudich A, Krämer SD, Wunderli-Allenspach H, Bassetti CL. Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 2006; 60: 489-98.
6. Spudich A, Kilic E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 2006; 9: 487-88.
7. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev. 2007; 54: 34-66.
8. Samoto K, Ikezaki K, Yokoyama N, Fukui M. P-glycoprotein expression in brain capillary endothelial cells after focal ischaemia in the rat. Neurol Res 1994; 16: 217-23.
9. Dazert P, Suofu Y, Grube M, et al. Differential regulation of transport proteins in the periinfarct region following reversible middle cerebral artery occlusion in rats. Neuroscience 2006; 142: 1071-9.
10. Ueno M, Nakagawa T, Huang CL, et al. The expression of Pglycoprotein is increased in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model. Neuropathol Appl Neurobiol 2009; 35: 147-55.
11. Lazarowski A, Caltana L, Merelli A, Rubio MD, Ramos AJ, Brusco A. Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci 2007; 258: 84-92.
12. Dan Y, Murakami H, Koyabu N, Ohtani H, Sawada Y. Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. J Pharm Pharmacol 2002; 54: 729-33.
13. Kilic E, Spudich A, Kilic U, et al. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain 2008; 131: 2679-89.
14. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia- reoxygenation injury. Am J Physiol Cell Physiol 2002; 282: C227-41.
15. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62(12): 3387-94.
16. Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 2003; 63: 7284-90.
17. Wartenberg M, Gronczynska S, Bekhite MM, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 2005; 113: 229-40.
18. Lotz C, Kelleher DK, Gassner B, Gekle M, Vaupel P, Thews O. Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. Oncol Rep 2007; 17(1): 239-44.
19. Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 2006; 8(2): 143-52.
20. Felix RA, Barrand MA. P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem 2002; 80, 64-72.
21. Robertson SJ, Kania KD, Hladky SB, Barrand MA. P-glycoprotein expression in immortalised rat brain endothelial cells: comparisons following exogenously applied hydrogen peroxide and after hypoxia- reoxygenation. J Neurochem 2009; 111: 132-41.
22. Hong H, Lu Y, Ji ZN, Liu GQ. Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J Neurochem 2006; 98: 1465-73.
23. Bankstahl JP, Hoffmann K, Bethmann K, Löscher W. Glutamate is critically involved in seizure-induced overexpression of Pglycoprotein in the brain. Neuropharmacology 2008; 54: 1006-16.
24. Liu X-D, Yang Z-H, Yang H-W. Repetitive/temporal hypoxia increased P-glycoprotein expression in cultured rat brain microvascular endothelial cells in vitro. Neurosci Lett 2008; 432: 184-87.
25. Tan KH, Purcell WM, Heales SJ, McLeod JD, Hurst RD. Evaluation of the role of P-glycoprotein in inflammation induced bloodbrain barrier damage. Neuroreport 2002; 13: 2593-7.
26. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002; 200: 629-38.
27. Armulik A, Genové G, Mäe M, et al. Pericytes regulate the bloodbrain barrier. Nature 2010; 468: 557-61.
28. Li L, Lundkvist A, Andersson D, et al. Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 2008; 28: 468-81.
29. Al Ahmad A, Taboada CB, Gassmann M, Ogunshola OO. Astrocytes and pericytes differentially modulate blood-brain barrier characteristics during development and hypoxic insult. J Cereb Blood Flow Metab 2011; 31: 693-705.
30. Pardridge WM, Golden PL, Kang YS, Bickel U: Brain microvascular and astrocytelocalization of P-glycoprotein. J Neurochem 1997; 68: 1278-85.
31. Golden PL, Pardridge WM. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 2000; 20: 165-81.
32. Regina A, Koman A, Piciotti M, et al. Mrp1 multidrug resistanceassociated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 1998; 71: 705-15.
33. Barrand MA, Robertson KJ, von Weikersthal SF. Comparisons of P-glycoprotein expression in isolated rat brain microvessels in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett 1995; 374: 179-83.
34. Seetharaman SL, Barrand MA, Maskell L, Scheper RJ. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 1998; 70: 1151-9.
35. ElAli A, Hermann DM. Apolipoprotein E controls ATP-binding cassette transporters in the ischaemic brain. Sci Signal 2010; 3: ra72.
36. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333-44.
37. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-8.
38. Vance JE, Hayashi H. Formation and function of apolipoprotein Econtaining lipoproteins in the nervous system. Biochim Biophys Acta 2010; 1801: 806-18.
39. Semenza G. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7: 345-50.
40. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996; 32A: 1039-50.
41. Ugocsai P, Hohenstatt A, Paragh G, et al. HIF-1beta determines ABCA1 expression under hypoxia in human macrophages. Int J Biochem Cell Biol 2010; 42: 241-52.
42. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279: 24218-25.
43. Comerford KM, Cummins EP, Taylor CT. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor1alphadependent P-glycoprotein expression in hypoxia. Cancer Res 2004; 64: 9057-61.
44. Liu M, Li D, Aneja R, Joshi HC, Xie S, Zhang C, Zhou J. PO(2)- dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J Biol Chem 2007; 282: 17581-6.
45. Hermann DM, Zechariah A. Implications of vascular endothelial growth factor for postischaemic neurovascular remodeling. J Cereb Blood Flow Metab 2009; 29: 1620-43.
46. Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010; 30: 1417-25.
47. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1?? increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 2007; 23: 6320-6332.
48. Helton R, Cui J, Scheel JR, et al. Brain-specific knock-out of hypoxia- inducible factor-1?? reduces rather than increases hypoxicischaemic damage. J Neurosci 2005; 16: 4099-107.
49. Kontos HA. Oxygen radicals in cerebral ischemia: the 2001 Willis lecture. Stroke 2001; 32: 2712-6.
50. Nwaozuzu O M, Sellers LA, Barrand MA. Signalling pathways influencing basal and H(2)O(2)-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem 2003; 87: 1043-51.
51. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol 2008; 101: 14D-19D.
52. Kahles T, Luedike P, Endres M, et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 2007; 38: 3000-6.
53. Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010; 8: e1000479.
54. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischaemic stroke. N Engl J Med 2008; 359: 1317-29.
55. Fisher M. New approaches to neuroprotective drug development. Stroke 2011; 42: S24-7.
56. Green AR. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol 2008; 153: S325-38.
57. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-77.
58. Davis S. Optimising Clinical Trial Design for Proof of Neuroprotection in Acute Ischaemic Stroke: The SAINT Clinical Trial Programme. Cerebrovasc Dis 2006; 22: 18-24.
59. Soontornmalai A, Vlaming ML, Fritschy JM. Differential, strainspecific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 2006; 138: 159-69.
60. Bollók M, Jánossy J, Krajcsi P. In: Nagy Z, Erdo F, ed. Recent advances and new strategies in stroke research. Kerala: Transworld Research Network. 2008; pp. 167-90.
61. Bath PM, Iddenden R, Bath FJ, Orgogozo JM; Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev 2001; 4:CD002087.
62. Nakase T, Yoshioka S, Suzuki A. Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischaemic stroke. BMC Neurol 2011; 11: 39.